Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ConsumerLab ginseng

This article was originally published in The Tan Sheet

Executive Summary

Ten of 12 ginseng supplements evaluated met CL standards for quality, label claims, disintegration and lack of contaminants and adulterants, online testing company announces Aug. 28. MotherNature.com's Korean ginseng had high levels of the pesticides hexachlorobenzene, quintozene, lindane, while Royal King's Chinese ginseng contained less than 10% of the claimed amount of ginsenosides, CL reports. Nature's Way herbal single Korean ginseng and Vitamin World's Chinese red ginseng were among the products that contained the proper amount of ginsenosides and that did not exceed acceptable levels of contaminants. CL last tested ginseng supplements in July 2000; the firm's findings of pesticide contamination in eight of 22 brands tested were featured on ABC News' 20/20 (1"The Tan Sheet" July 17, 2000, p. 15)...

You may also be interested in...



AHPA/CRN Challenge Reliability Of ConsumerLab.com Data

The lack of peer review of the tests employed by ConsumerLab.com may put into question the accuracy of the independent labs' findings, AHPA and CRN tell their members in a joint statement July 13.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel